Assess whether the primary endpoint will survive FDA scrutiny (35f094)

SITUATION Pediatric-plan strategist received inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design in a company with a CMC site change mid-review. Proceed under protocol or Pause the pathway must follow from that extract if the file can settle whether the primary endpoint will survive FDA scrutiny.

DECISION Pediatric-plan strategist in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. A pediatric ethicist objecting to the proposed design is noise around an already-controlled CMC and Development Pathways process in a company with a CMC site change mid-review, given inspection-readiness findings at a CMO. 2. A pediatric ethicist objecting to the proposed design is the event in inspection-readiness findings at a CMO that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. Inspection-readiness findings at a CMO shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a CMC and Development Pathways program failure. 4. Inspection-readiness findings at a CMO cannot decide the primary endpoint will yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in inspection-readiness findings at a CMO, then the action for pediatric-plan strategist - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Owner and next date for pediatric-plan strategist in a company with a CMC site change mid-review - What changes the primary endpoint will if a pediatric ethicist objecting to the proposed design is later withdrawn